Effective Wednesday, November 13, 2019, the new Mycoplasma genitalium assay is now available using the Aptima target nucleic acid amplification test (NAAT) for the qualitative detection of ribosomal RNA (rRNA) from Mycoplasma genitalium to aid in the diagnosis of M. genitalium urogenital infections in male and female patients.
Please join us in welcoming our new pathologists to Spectrum Health Regional Laboratory!
Effective May 20, 2019, Spectrum Health Regional Laboratory Cytogenetics Department is pleased to announce the launch of a new microarray platform AffymetrixTM Cytoscan® HD. The Affymetrix Cytoscan HD is designed for the accurate and comprehensive analysis of chromosomal variants in the human genome.
Effective September 1st, 2018 the Advanced Technology Laboratories – Cytogenetics Department is proud to announce a new test: Array Comparative Genomic Hybridization (aCGH), Prenatal.
Effective immediately, Oxidative Burst by Flow Cytometry (#LAB2111414) will no longer require submission of the biological mother’s sample. An adult control specimen will still be required along with the patient’s specimen. For more information on specimen collection, please visit the Laboratory Catalog.
Questions may be directed to the Flow Cytometry Laboratory using the “Contact Us” link above.
An updated BCR-ABL1 t[9;22] RT-PCR assay went live on Jan 31, 2018. The BCR-ABL major and minor fusion transcripts are measured and reported separately after this update. The quantities of BCR-ABL1 major breakpoints fusion transcripts (type e13a2 and/or e14a2) are detected by FDA approved QuantideX® qPCR BCR-ABL IS Kit and the result is calibrated and reported on the International Scale (%IS). The quantities of BCR-ABL minor fusion transcripts are detected by QuantideX qPCR BCR-ABL minor kit and the result is reported as BCR-ABL1 to ABL1 ratio (%). This update provides more precise and standard measurements of BCR-ABL fusion RNA and supports the consistency of patient care in t(9;22) positive CML patients during monitoring of treatment with Tyrosine Kinase Inhibitors (TKIs).
Questions may be directed to the Molecular Diagnostics Laboratory using the “Contact Us” link above.
Lab Catalog link: LAB3222022: BCR-ABL1 t[9;22] RT- PCR
High sensitivity flow cytometry testing for paroxysmal nocturnal hemoglobinuria (PNH) is a test done on patient’s peripheral blood to screen for the presence or absence of PNH clones and/or to follow PNH clonal populations. The lower limit of detection of a PNH clone for the Spectrum Health laboratory has been validated as 0.01% (1:10,000) for red cells, 0.01% (1:10,000) for granulocytes and 0.1% for monocytes (1:1000).
The results from PNH flow cytometry testing can guide the clinical team in classifying a patient’s disease appropriately, analyzing the risk of disease progression, and choosing appropriate testing to monitor response to treatment. Therefore, the PNH flow cytometry test result will now include a pathologist’s interpretation based on the new recommendations given in Updated ICCS/ESCCA Consensus Guidelines for the Clinical Utility of Testing for GPI-Anchor Deficient Clones in Paroxysmal Nocturnal Hemoglobinuria (PNH) and other Bone Marrow Disorders (Accepted article by Dezern and Borowitz, doi: 10.1002/cyto.b.21608).
The Spectrum Health Flow Cytometry Laboratory is pleased to announce that it has attained status as a Children’s Oncology Group (COG) approved laboratory for minimal residual disease (MRD) testing for patients with B lymphoblastic leukemia (B-ALL). This is a reflection of the expertise and dedication of the entire flow cytometry team to accomplish this 3-year project. It also highlights the strong support and collaboration between the laboratory and pediatric hematology oncology team.
Spectrum Health Advanced Technology Laboratories are proud to announce that the first and only FDA-approved blood test for colorectal cancer screening is now available at Spectrum Health Molecular Diagnostics Laboratory. The Epi proColon Septin 9 Methylation Analysis test is indicated to screen adults of either sex, 50 years or older, defined as average risk for colorectal cancer (CRC), who have been offered and have a history of not completing CRC screening.